The 150-Year Lifespan: Science or Fantasy?
In 2024, a mouse study extended lifespan by 45% using a cocktail of rapamycin, metformin, and a new AI-designed senolytic. The mice didn't just live longer—they stayed healthy longer. The "healthspan" expanded nearly as much as the lifespan.
Translating to humans: if the same mechanism works, the average lifespan could reach 126. The optimistic ceiling: 150. The catch: the trials are in mice. The FDA requires 10-year studies for anti-aging drugs. The first human data arrives in 2034.
The wealthy are already "biohacking." The "Longevity Fund" in Silicon Valley has $4.2B under management. They invest in startups that measure biological age (not birth age) and reverse it. One portfolio company claims a 14% reversal in 8 months.
The equity nightmare: if only the rich can afford 150 years, the wealth gap becomes... eternal. A 150-year life requires rethinking retirement, inheritance, and "generational wealth"—which now means something very different.
2024 年，一项小鼠研究使用雷帕霉素、二甲双胍和一种新的 AI 设计的衰老细胞清除剂的组合，将寿命延长了 45%。小鼠不仅活得更长——而且保持健康的时间更长。"健康寿命"的扩展几乎与寿命一样多。
转化到人类：如果同样的机制有效，平均寿命可能达到 126 岁。乐观上限：150 岁。问题：试验是在小鼠身上进行的。FDA 要求抗衰老药物进行 10 年研究。第一批人类数据将于 2034 年到达。
富人已经在"生物黑客"。硅谷的"长寿基金"管理着 42 亿美元。他们投资于测量生物年龄（不是出生年龄）并逆转它的初创公司。一家投资组合公司声称在 8 个月内逆转了 14%。
公平性的噩梦：如果只有富人能负担得起 150 年，贫富差距变得……永恒。150 年的生命需要重新思考退休、继承和"世代财富"——现在这意味着非常不同的东西。